[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
A prospective randomized study in a total of 36 patients with previously untreated advanced squamous cell carcinomas of the head and neck was performed. 20 patients were in group of 120-hour continuous infusion 5-Fu and bolus cisplatin (continuous group). Over-all response rates of continuous group were 90% (complete response 20%, partial response 70%) and of conventional group were 43.8% (6.3%, 37.5%). The differences in the over-all response rates of two groups were statistically significant at P = 0.0039. There was no difference between the two chemotherapy toxicity (P > 0.05), and the toxicity was clinically acceptable. The authors concluded that two or three course of 120-hour 5-Fu continuous infusion and bolus cisplatin is highly effective and safe adjuvant treatment in patients with advanced carcinoma of the head and neck.
Zhou
T
T
Cancer Hospital, Sun Yet-Sen Medical University, Guangzhou.
Zeng
Z
Z
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D002945:Cisplatin; D005472:Fluorouracil